Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — Investor Presentation (November 2025)
21 slides from Cellbxhealth's investor presentation, November 2025
Slide 1: Enabling precision medicine with a simple blood test
Enabling precision medicine with a simple blood test Investor Presentation – Nov 2025 © CelLBxHealth plc 2025 CONFIDENTIAL
Slide 2: Legal Disclaimer
LSE AIM: CLBX Legal Disclaimer LSE AIM: AGL OTCQX: ANPCY THIS PRESENTATION IS CONFIDENTIAL AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES
Slide 3: Presenting today
Presenting today Peter Collins Dr. Jan Groen CEO Executive Chairman © CelLBxHealth plc 2025 CONFIDENTIAL 3
Slide 4: Opportunity summary
Opportunity summary Driving the next generation of precision cancer diagnostics Market Opportunity • $12.6b CTC market, projected to reach $25b by 2030 (CAGR 12.2%) Clinical Need Now • Independent expert consensus confirms clinical relevance of CTCs and identifies the Parsortix platform as leading n
Slide 5: Summary of funding
Summary of funding • Successful fundraise of £6.8m gross announced 24 November 2025 • Strong support from our larger shareholders, with a number significantly increasing their positions • Retail offer of up to £1m at an issue price of 1.0 pence per Ordinary Share • GM - 2:00 pm on 15 December 2025 •
Slide 6: Cancer: a significant and growing global issue
Cancer: a significant and growing global issue 1 in 2 diagnosed with cancer in their lifetime 19 million new cancer cases p.a., with 49 million people living with cancer (5-year prevalence) 65% growth in global cancer cases by 2050, with 31 million new cases p.a. by 2050 $25.2 trillion estimated glo
Slide 7: Current care fails to address patient needs
Current care fails to address patient needs • Tissue biopsies are the standard of care to confirm cancer diagnosis and identify patients for precision medicine • They are painful, costly and unsuitable for repeated use • Cancer evolves, making tissue biopsies quickly outdated for treatment decisions
Slide 8: CTCs overcome limitations of tissue biopsy and ctDNA
CTCs overcome limitations of tissue biopsy and ctDNA Tissue biopsy (1) • Standard of care • Cancer cells taken directly from the tumour 1. Tumour • Limited to the site of the biopsy • Invasive procedure with risks. Unsuitable for repeat testing Blood vessel Liquid biopsy 3. ctDNA CTCs (2) 2. CTCs •
Slide 9: Independent expert consensus confirms importance of CTCs
Independent expert consensus confirms importance of CTCs • Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years • CTCs provide distinct and impactful information that is not captured by circulating tumour DNA (ctDNA) • 40% of the expert panel identified
Slide 10: The Parsortix platform provides a critical component
The Parsortix® platform provides a critical component • Patented, scalable platform for capturing circulating tumour cells (CTCs) from blood • Enables minimally invasive, cost-effective and repeatable testing of cancer cells • Broad validation across 24 cancer types, accounting for >90% of solid tum
Slide 11: Proven platform
Proven platform Commercial validation • >50 platforms sold post-FDA with 80% growth in sales (2022 vs. 2024) • 15 services contracts generated £2 million in revenue • >1,800 patient samples analysed for customers Regulatory excellence • FDA-cleared platform for harvest of CTCs • Manufactured under I
Slide 12: Product and laboratory services focus
Product and laboratory services focus Streamlining of operations completed by 2025 year-end Focus on three key pillars: 1. Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs* and clinical lab partnerships 2. Laboratory services: Clinical trial support and assay
Slide 13: Strategic partnerships driving product adoption
Strategic partnerships driving product adoption Diagnostic Market expansion applying CTCs to existing tissue and DNA-based tests Pharma already engaging with CelLBxHealth and partners Transferring tissue-based tests to CTCs Transferring DNA-based tests to CTCs BioView • Collaboration to develop HER2
Slide 14: Business model
Business model Target customer 2026/2027 target CelLBxHealth Strategic Partnerships type by customer type Sales pipeline* CRO 4 £12.6m gross Lab Services 12 £4.5m weighted Clinical Lab 4 Platform & Imaging or tissue/DNA Partners have 2026/2027 target consumables test providers significant by custome
Slide 15: Milestones and Outlook
Milestones and Outlook Commercial milestones – 18 months to June 2027 Product sales • Targeting contracts with four CROs and clinical labs • Two technology transfer agreements to US clinical labs • Successful bridging studies across multiple tissue-based tests Outlook • Revenues of c. £1.6m in year
Slide 16: Anticipated news feed and quarterly reporting
Anticipated news feed and quarterly reporting Company Announcement Date Roche Tissue Diagnostics Successful pilot study demonstrating CTC workflow on Roche’s tissue-based platform Q4-2025 US CRO Strategic CRO partnership in the US for clinical trials and LDT development Q4-2025 Pharma Follow on labo
Slide 17: Financial reset
Financial reset A lean and focused CelLBxHealth, positioned for long-term, independent growth Metric 2024 2025 2026 Annual Cash Burn £14.5m £12.7m £5.5m Gross Margin 62% 62% 71% EBITDA (£12.3m) (£13.0m) (£3.9m) positive from late 2028 Headcount 130 108 c. 44 (~60% reduction vs 2025) • Restructure of
Slide 18: Acquisitions in the liquid biopsy market (2020-2025)
Acquisitions in the liquid biopsy market (2020-2025) Company acquired Company Date Region Value Analyte Purchasing (USD $) Freenome Exact Sciences 2025 US $700m Multiomics C2i Genomics Veracyte 2024 MENA/US $70m MRD Haystack Oncology Quest Diagnostics 2023 US/EU $450m MRD Yourgene Health Novacyt 202
Slide 19: Use of funds
Use of funds % £m Key Objective Development of two products in brain and lung cancer, and strategic Research and Development 32% £1.9m partnerships for validation of CTCs on tissue-based tests Sales and Marketing 17% £1.0m Deliver revenues per commercial roadmap; S&M headcount increase c.60% headcou
Slide 20: Summary of funding
Summary of funding • Successful fundraise of £6.8m gross announced 24 November 2025 • Strong support from our larger shareholders, with a number significantly increasing their positions • Retail offer of up to £1m at an issue price of 1.0 pence per Ordinary Share • GM - 2:00 pm on 15 December 2025 •
Slide 21: 21
21